- Open Access
β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons
Molecular Pain volume 10, Article number: 50 (2014)
Despite advances in understanding the signaling mechanisms involved in the development and maintenance of chronic pain, the pharmacologic treatment of chronic pain has seen little advancement. Agonists at the mu opioid receptor (MOPr) continue to be vital in the treatment of many forms of chronic pain, but side-effects limit their clinical utility and range from relatively mild, such as constipation, to major, such as addiction and dependence. Additionally, chronic activation of MOPr results in pain hypersensitivity known as opioid-induced hyperalgesia (OIH), and we have shown recently that recruitment of β-arrestin2 to MOPr, away from transient potential vanilloid eceptor type 1 (TRPV1) in primary sensory neurons contributes to this phenomenon. The delta opioid receptor (DOPr) has become a promising target for the treatment of chronic pain, but little is known about the effects of chronic activation of DOPr on nociceptor sensitivity and OIH. Here we report that chronic activation of DOPr by the DOPr-selective agonist, SNC80, results in the sensitization of TRPV1 and behavioral signs of OIH via β-arrestin2 recruitment to DOPr and away from TRPV1. Conversely, chronic treatment with ARM390, a DOPr-selective agonist that does not recruit β-arrestin2, neither sensitized TRPV1 nor produced OIH. Interestingly, the effect of SNC80 to sensitize TRPV1 is species-dependent, as rats developed OIH but mice did not. Taken together, the reported data identify a novel side-effect of chronic administration of β-arrestin2-biased DOPr agonists and highlight the importance of potential species-specific effects of DOPr agonists.
The management of chronic pain is a critical healthcare problem associated with soaring annual costs and immense physical and psychological burden to patients. Mild chronic pain can often be effectively controlled with acetaminophen or non-steroidal anti-inflammatory drugs. However, agonists acting at mu opioid receptors (MOPr) represent a mainstay treatment for moderate to severe chronic pain. Prolonged use of MOPr agonists can lead to severe side-effects, such as addiction, dependence, tolerance, constipation and respiratory depression, that limit their clinical utility . Furthermore, chronic exposure to agonists at MOPr precipitates nociceptive hypersensitivity known as opioid-induced hyperalgesia (OIH) . Although OIH has been well characterized in animal models [3–14] and clinical reviews/reports [8, 15–19], OIH treatment in patients is difficult , in part because increasing opioid doses exacerbate OIH symptoms. The mechanisms underlying development and maintenance of OIH appear to have complicated central [6, 16, 20] and peripheral [13, 21] components, but the transient receptor potential vanilloid type 1 receptor (TRPV1) appears to play a key role in the development and/or maintenance of OIH , especially in primary afferent neurons .
TRPV1 is a nonselective ligand-gated ion channel that is activated by heat, acid, and chemical agonists, including the selective agonist capsaicin [22–24]. TRPV1 is subject to dynamic regulation, mainly via phosphorylation (sensitization) and dephosphorylation (desensitization) by a several kinases . Additionally, recent studies identified that the arrestin family of proteins, namely β-arrestin2, dynamically regulates the activity of several TRP channels [26, 27], including TRPV1 [21, 28]. Specifically, β-arrestin2 associates with TRPV1 and scaffolds phosphodiesterase PDE4D5, which decreases cyclic AMP levels leading to the desensitization of TRPV1 via reduced protein kinase A (PKA) activity . We have recently demonstrated that chronic activation of peripheral MOPr with β-arrestin2-biased MOPr agonists leads to recruitment of β-arrestin2 to MOPr, a reduced association between β-arrestin2 and TRPV1 and a resulting sensitization of TRPV1 in primary sensory neurons, precipitating behavioral symptoms of OIH .
Since few other options exist that are safe and effective for the treatment of chronic pain, new and innovative approaches are needed to identify novel targets. Delta opioid receptors (DOPr) are gaining considerable attention as promising new targets in the treatment of chronic pain [29–32]. DOPr is a seven transmembrane spanning receptor, often termed G protein-coupled receptor (GPCR), that is expressed in the central and peripheral nervous system and inhibits nociceptive signaling when activated by agonists . DOPr agonists are antinociceptive in behavioral models [29, 30] and are highly efficacious at reducing chronic pain with reduced tolerance and dependence when compared to MOPr agonists [33–36]. Furthermore, DOPr agonists have shown promise as potential treatments for depression , which is often comorbid with chronic pain . Due to their reduced side-effect profile, efficacy during chronic treatment, and potential efficacy with comorbid disorders, DOPr agonists hold great promise as novel therapeutics for the treatment of pain. However, few have studied side-effects of chronic DOPr activation or evaluated whether DOPr agonists are capable of producing OIH following chronic administration. Here we show that, like MOPr agonists, chronic administration of β-arrestin2-biased agonists of DOPr also sensitizes TRPV1 on primary sensory neurons and leads to the development of behavioral symptoms of OIH in rats. Interestingly, β-arrestin2 cross-talk with DOR/TRPV1 is species dependent, as DOPr agonists failed to sensitize TRPV1 or produce behavioral symptoms of OIH in mice or in primary sensory neurons from mice.
DOPr and TRPV1 are co-localized on peptidergic and nonpeptidergic sensory neurons
Studies in mice demonstrate that DOPr and TRPV1 do not colocalize in sensory neurons of the dorsal root ganglia (DRG) and that DOPr is found primarily in nonpeptidergic, small-diameter neurons that give rise to unmyelinated axons . For this reason, it was proposed that DOPr agonists affect only mechanical, not thermal, nociception , but this is in contrast to the established role that DOPr agonists have on thermal allodynia in rats at both spinal  and peripheral locations [42–45]. Additionally, DOPr and TRPV1 colocalize in rat dental pulp  and primary afferent neurons of the rat DRG , with DOPr present in both peptidergic and nonpeptidergic DRG neurons . Since sensory neurons from the rat trigeminal ganglia (TG) were used for in vitro studies, we qualitatively evaluated DOPr and TRPV1 expression relationships in rat TG tissue sections with immunohistochemistry and confocal microscopy. Results demonstrate DOPr colocalization with TRPV1 in a subpopulation of both nonpeptidergic/IB4+ (arrows) and IB4- (arrowheads) sensory neurons (Figure 1). The extent of colocalization was not quantified, but it was estimated that roughly 40% of all neurons expressed TRPV1, 40% expressed DOPr, and approximately half of the cells that were positive for TRPV1 were also positive for DOPr (Figure 1). These data support the hypothesis that DOPr activation could directly affect TRPV1 channel activity and/or sensitivity to a stimulus.
Pretreatment with SNC80, not ARM390, recruits β-arrestin2 to DOR, away from TRPV1, in primary sensory neurons
Our previous work with MOPr demonstrated that β-arrestin2-biased agonists differentially recruit β-arrestin2 to MOPr and away from TRPV1 . Given that DOPr and TRPV1 are coexpressed in rat sensory neurons (Figure 1) and MOPr and DOPr signal through similar effector mechanisms with respect to β-arrestin2 [30, 48–52], it follows that activation of DOPr with ligands that recruit β-arrestin2 would also reduce β-arrestin2 association with TRPV1. To test this, rat TG neurons were treated with DOPr-selective agonists, SNC80 (1 μM, 30 min) or ARM390 (1 μM, 30 min) and the association of β-arrestin2 with DOPr or TRPV1 was evaluated by coimmunoprecipitation. SNC80 and ARM390 are structurally similar and have similar affinities and efficacies for DOPr activation and inhibition of allodynia [53–55]. However, SNC80 effectively recruits β-arrestin2 to DOPr, while ARM390 does not [53, 55–57]. Following treatment with SNC80 there was a significant increase in the association of β-arrestin2 and DOPr and a significant decrease in the association of β-arrestin2 and TRPV1 (Figure 2). Consistent with earlier reports on biased agonist activity [49, 54–57], ARM390 did not recruit β-arrestin2 to DOPr and did not affect the association of β-arrestin2 and TRPV1 (Figure 2).
Pretreatment with SNC80, not ARM390, produces species-dependent TRPV1 sensitization
β-arrestin2 desensitizes TRPV1  and recruitment of β-arrestin2 away from TRPV1 with chronic administration of MOPr agonists results in sensitized TRPV1 and behavioral symptoms of OIH . Treatment of rat sensory neurons with SNC80 results in the recruitment of β-arrestin2 to DOPr, away from TRPV1 (Figure 2), but the functional significance remains unclear. To evaluate this in vitro we treated cultured sensory neurons with SNC80 (1 μM, 30 min) or ARM390 (1 μM, 30 min) prior to exposure to the TRPV1 agonist, capsaicin (CAP, 50 nM), and monitored intracellular calcium accumulation as a response to TRPV1 activation, similar to previous studies [21, 28, 58–61]. To identify positive DOPr expression, rat neurons were nucleofected with YFP-labeled rat DOPr and recordings were taken from YFP-positive cells only. Pretreatment of sensory neurons with SNC80 significantly enhanced responses to CAP, whereas ARM390 had no effect (Figure 3C). TRPV1 was also significantly sensitized in sensory neurons nucleofected with YFP-labeled human DOPr (Figure 3B) following SNC80 pretreatment compared to ARM390 (Figure 3). However, in sensory neurons nucleofected with YFP-labeled mouse DOPr (Figure 3D), SNC80 sensitization of TRPV1 responses was significantly less than that seen for rat-DOPr- or human-DOPr-nucleofected neurons (Figure 3). Nucleofection efficiency (approximately 10-20%) was similar for rat, human, and mouse DOPr cDNAs. The concentrations of SNC80 and ARM390 chosen for the current study were validated in previous reports [55, 57], but to verify that the concentrations of SNC80 and ARM390 were effective in our culture system, we evaluated the ability of SNC80 and ARM390 to acutely inhibit N-type voltage-gated calcium channels (VGCC), as we have before . Application of SNC80 (1 μM, 5 min) or ARM390 (1 μM, 5 min) inhibited N-type VGCC by 44 ± 5 and 51 ± 4%, respectively (Figure 4).
Chronic administration of SNC80, not ARM390, produces behavioral symptoms of OIH in rats, not mice
To determine the physiological significance of DOPr-mediated sensitization of TRPV1, intraplantar injections were performed once daily for five days with SNC80 (20 μg) or ARM390 (20 μg). Administering daily opioid injections is a common model of OIH in animals  and has been used with peripheral injections  to evaluate the effects of chronic opioid administration directly on primary sensory neurons and avoid confounding central mechanisms. Rats injected chronically with SNC80, not ARM390, displayed a significant reduction in thermal sensitivity (Figure 5A) and a significant increase in the sensitivity to CAP (Figure 5B). Alternatively, SNC80 induced neither thermal (Figure 5C) nor CAP (Figure 5D) sensitivity in mice following chronic injections, consistent with reduced measures of TRPV1 response sensitization (Figure 3). The doses of SNC80 and ARM390 chosen for these studies have been validated by others  and were equally effective at inhibiting thermal allodynia when administered acutely (Figure 6).
Chronic administration of agonists at MOPr produces OIH, which limits the clinical efficacy of opioids in the treatment of chronic pain . Furthermore, OIH is difficult to treat, as increasing opioid dose results in a further exaggeration of pain symptoms . Agonists at DOPr hold promise in the treatment of chronic pain [29, 32], but a potential role for DOPr agonists in the development of OIH has not been evaluated. Understanding DOPr-mediated OIH and the potential mechanisms involved is critical to developing effective DOPr agonists for the treatment of chronic pain.
This is the first demonstration of chronic administration of DOPr agonists producing cellular and behavioral characteristics of OIH. Results presented here demonstrate that β-arrestin2 is recruited to DOPr, thereby decreasing TRPV1/β-arrestin2 association. Furthermore, TRPV1 sensitization is biased-agonist- and species-dependent, as cells expressing human or rat DOR display significantly greater enhancement than cells expressing mouse DOR. Furthermore, chronic administration of DOR agonists in vivo produces behavioral signs of OIH in rats, not mice, supporting the concept that DOR-TRPV1 cross-talk is species-dependent.
The location and function of DOPr on primary sensory neurons remains controversial. Some have shown that DOPr is not expressed in TRPV1-positive DRG sensory neurons in genetically-modified mice  and contend that DOPr agonists only inhibit mechanical, not thermal, nociception . Others have demonstrated that DOPr agonists effectively inhibit thermal allodynia in rats when administered spinally  or peripherally [42–45]. Additionally, DOPr and TRPV1 colocalize in rat dental pulp  and primary afferent neurons of the rat DRG , with DOPr present in both peptidergic and nonpeptidergic DRG neurons . Taken together with immunohistochemical results presented here in rats (Figure 1), it is clear that the distribution and function of DOPr is different in mice and rats, and presumably humans (Figure 3), and caution is advised when drawing broad conclusions about the function of DOPr across multiple species. Furthermore, clinical and preclinical trials evaluating DOPr agonists as novel analgesics should consider the use of different species whenever possible.The differential sensitization of TRPV1 by DOPr from rat, human, or mouse origin (Figure 3) suggests a functional difference from unique amino acid sequence, not a difference in localization or expression, as nucleofection efficiency was similar regardless of cDNA origin. Furthermore, the same cells were used for the investigation of DOPr species differences to control for the expression of β-arrestin2 and TRPV1. However, amino acid sequence comparison would likely serve a valuable role in the identification of species-unique differences that govern agonist effects, both within the receptor itself and within cross-signaling platforms such as β-arrestin paradigms highlighted in these studies. While acute inhibition of N-type VGCC was used as a control experiment to verify that SNC80 and ARM390 were equally effective in our culture system, kinetic studies would also be valuable to determine if differences manifest following prolonged pretreatment times, due to kinetic differences in β-arrestin2 recruitment.
DOPr agonists are effective in the treatment of chronic pain across a variety of preclinical models [29, 30] and demonstrate reduced tolerance and dependence when compared to MOPr agonists [33–36]. Chronic pain is often comorbid with psychological disorders, such as depression , and DOPr agonists have demonstrated efficacy in animal models of depression . For these reasons it is tempting to speculate broad use for DOPr agonists as future analgesics, but caution must again be exercised. DOPr agonists also have the potential to develop side-effects, such as seizures, that may limit clinical efficacy . Unlike MOPr, DOPr undergoes unique trafficking [34, 36, 57], which may decrease the broad application of DOPr agonists for the treatment of chronic pain. However, due to their overall reduced side-effect profile and continued efficacy during chronic treatments in preclinical models, DOPr agonists hold promise as novel therapeutics for the treatment of chronic pain. In our previous study , we demonstrated that agonists at MOPr that did not recruit β-arrestin2 neither sensitized TRPV1 nor produced symptoms of OIH, and may therefore hold clinical promise. However, ligands that activate MOPr would still be expected to produce tolerance and dependence, so DOPr agonists might be better suited for the treatment of chronic pain. Results presented here highlight that DOPr agonists that do not recruit β-arrestin2 merit further investigation as novel therapeutics for the treatment of chronic pain for their potential to effectively manage chronic pain without inducing DOPr-mediated OIH. Future clinical and preclinical trials should consider the use of different species when evaluating DOPr agonists as novel analgesics.
All procedures using animals were approved by the Institutional Animal Care and Use Committee of The University of Texas Health Science Center at San Antonio and were conducted in accordance with policies for the ethical treatment of animals established by the National Institutes of Health and International Association for the Study of Pain. Male C57BL6 mice (22–25 g) and male Sprague–Dawley rats (175–200 g) used in these studies were from Charles River (Wilmington, MA).
(+)-4-[(αR)-α-((2S,5R)-4-Allyl-2,5-dimethyl-1-piperazinyl)-3-methoxybenzyl]-N,N-diethylbenzamide (SNC80) and N,N-Diethyl-4-(phenyl-4-piperidinylidenemethyl)-benzamide hydrochloride (ARM390) were purchased from Tocris. All tissue culture reagents and media were from Invitrogen, and all other drugs and chemicals were from Sigma Aldrich unless otherwise indicated.
All injections were given intraplantarly in 50 μl (rat) or 10 μl (mouse) volumes via a 28-gauge needle inserted through the lateral footpad just under the skin to minimize tissue damage. Drug stocks were dissolved in PBS, or PBS with 2% Tween20 (for experiments with DMSO). Paw withdrawal latency to a thermal stimulus was measured by blinded observers with a plantar test apparatus (IITC, Woodland Hills, CA) as previously described . Nocifensive behavior in response to CAP (Tocris Bioscience, Minneapolis, MN; 0.5 μg and 0.1 μg for rats and mice, respectively) was defined as hindpaw lifting, flinching, or licking and was quantified by blinded observers for 5 min as previously described [21, 61].
Primary TG neuron culture
Rat TG neurons were cultured as described previously . Briefly, rats were sacrificed by decapitation, TG neurons were dissociated and digested with collagenase/trypsin, cells were centrifuged, enzymes were aspirated, and the cell pellet was re-suspended in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal bovine serum, 100 ng/ml nerve growth factor (Harlan), 1% penicillin/streptomycin and 1% glutamine, then placed on poly-D-lysine coated 10 cm plates (BD; co-immunoprecipitation), or poly-D-lysine- and laminin-coated coverslips (BD; electrophysiology, calcium imaging). Cultures were maintained at 37° C, 5% CO2 for 5–7 d for co-immunoprecipitation experiments and 1–2 d for calcium imaging and electrophysiology.
For calcium imaging and electrophysiology experiments, TG neurons were isolated as described above and nucleofected (Lonza) as described previously [21, 63, 64] prior to plating on poly-D-lysine/laminin-coated coverslips. Cells were imaged 48–72 h following plating. Rat and mouse DOPr-YFP cDNAs were a generous gift from Dr. Nigel Bunnett (Monash University). Human DOPr cDNA was purchased from Missouri S&T (OPRD1) and cloned into pEYFP-N1 (Clontech).
The TGs from a male Sprague Dawley rat were obtained, processed and stained as previously described [65, 66] with IB4 isolectin from Griffonia simplicifolia labeled with Alex Fluor 488 conjugate (Molecular Probes I21411 at 1:1000 dilution), and rabbit anti-rat DOPr (Millipore AB5503 at 1:250 dilution) and guinea pig anti-rat TRPV1 (Neuromics GP14100 at 1:2000 dilution) polyclonal antibodies. Species-appropriate Alexa Fluor secondary antibodies (Molecular Probes at 1:200 dilution) were used to visualize DOPr (Alexa Fluor 568) and TRPV1 (Alexa Fluor 633). Immunofluorescence was evaluated and images were obtained with the use of a Nikon 90i microscope equipped with a C1si laser scanning confocal imaging system (Nikon, Melville, NY). Images were processed for illustration purposes with Adobe Photoshop CS2 (Adobe , San Jose, CA).
TG neuron cultures were pretreated as indicated, harvested by scraping, homogenized, and plasma membranes were isolated by centrifugation. Total protein was quantified using the Bradford assay, and equal amounts of protein from each treatment were immunoprecipitated and analyzed as described previously  using antibodies to TRPV1 (Santa Cruz, R130), β-arrestin2 (Santa Cruz, H9) or DOPr (Abcam, ab66317). Antibody efficacy and specificity were verified by the manufacturers and BLAST sequence analysis, and used in previous publications [21, 28, 58, 60, 67].
Changes in intracellular calcium concentration were measured as described previously . Briefly, TG neurons cultured on poly-D-lysine-coated coverslips were incubated with Fura-2 AM (2 μM, 30 min, 37°C) in the presence of 0.05% Pluronic (EMD Millipore) in a standard extracellular solution (SES) containing (in mM): 140 NaCl, 5 KCl, 2 CaCl2, 1 MgCl2, 10 D-glucose, pH 7.4. Nucleofected cells were identified by the presence of YFP.
Opioid-mediated inhibition of N-type VGCC was measured as described . Briefly, patch clamp capillaries (2–4 MΩ) were pulled from borosilicate glass (World Precision Instruments, Sarasota, FL) with a micropipette puller (Narishige, Japan). Currents were measured in whole-cell configuration with an EPC-10 amplifier (HEKA, Germany) and analyzed with Patch Master software (HEKA). Giga seal and whole-cell configuration were established in SES containing (in mM): 145 NaCl, 5 KCl, 2 MgCl2, 2CaCl2, 10 HEPES, and 10 glucose (pH 7.4), then changed to extracellular solution containing (in mM): 145 NMDG-Cl, 2 MgCl2, 3 BaCl2, 10 HEPES, and 10 glucose (pH 7.4). Pipette solution contained (in mM): 120 CsCl, 1 MgCl2, 10 EGTA, 10 HEPES, 4 Mg-ATP, 0.3 Na-GTP (pH 7.2). The voltage-gated Ca2+currents were activated by pulses from −70 to 25 mV (150 ms, 5 mV steps, 5 s intervals) from a holding potential of −70 mV. SNC80 (1 μM) and ARM390 (1 μM) were applied via bath application and only cells that showed reversible effects of drug treatment were included in analysis. The identity of the currents was verified with application of the N-type calcium channel inhibitor α-conotoxin (Alomone Labs, Israel).
Delta opioid receptor
Mu opioid receptor
Phosphate buffered saline-Tween
Protein kinase A
Transient receptor potential family V1
N-type voltage-gated calcium channels
Yellow fluorescent protein.
Williams JT, Ingram SL, Henderson G, Chavkin C, von Zastrow M, Schulz S, Koch T, Evans CJ, Christie MJ: Regulation of mu-opioid receptors: desensitization, phosphorylation, internalization, and tolerance. Pharmacol Rev 2013, 65: 223–254.
Angst MS, Clark JD: Opioid-induced hyperalgesia: a qualitative systematic review. Anesthesiology 2006, 104: 570–587.
Chen Y, Yang C, Wang ZJ: Ca2+/calmodulin-dependent protein kinase II alpha is required for the initiation and maintenance of opioid-induced hyperalgesia. J Neurosci 2010, 30: 38–46.
Eijkelkamp N, Wang H, Garza-Carbajal A, Willemen HL, Zwartkruis FJ, Wood JN, Dantzer R, Kelley KW, Heijnen CJ, Kavelaars A: Low nociceptor GRK2 prolongs prostaglandin E2 hyperalgesia via biased cAMP signaling to Epac/Rap1, protein kinase Cepsilon, and MEK/ERK. J Neurosci 2010, 30: 12806–12815.
Elhabazi K, Trigo JM, Mollereau C, Mouledous L, Zajac JM, Bihel F, Schmitt M, Bourguignon JJ, Meziane H, Petit-demouliere B, Bockel F, Maldonado R, Simonin F: Involvement of neuropeptide FF receptors in neuroadaptive responses to acute and chronic opiate treatments. Br J Pharmacol 2012, 165: 424–435.
Ferrini F, Trang T, Mattioli TA, Laffray S, Del’Guidice T, Lorenzo LE, Castonguay A, Doyon N, Zhang W, Godin AG, Mohr D, Beggs S, Vandal K, Beaulieu JM, Cahill CM, Salter MW, De Koninck Y: Morphine hyperalgesia gated through microglia-mediated disruption of neuronal Cl(−) homeostasis. Nat Neurosci 2013, 16: 183–192.
Krishnan S, Salter A, Sullivan T, Gentgall M, White J, Rolan P: Comparison of pain models to detect opioid-induced hyperalgesia. J Pain Res 2012, 5: 99–106.
Li X, Angst MS, Clark JD: A murine model of opioid-induced hyperalgesia. Brain Res Mol Brain Res 2001, 86: 56–62.
Lian B, Vera-Portocarrero L, King T, Ossipov MH, Porreca F: Opioid-induced latent sensitization in a model of non-inflammatory viscerosomatic hypersensitivity. Brain Res 2010, 1358: 64–70.
Liang DY, Liao G, Wang J, Usuka J, Guo Y, Peltz G, Clark JD: A genetic analysis of opioid-induced hyperalgesia in mice. Anesthesiology 2006, 104: 1054–1062.
Mao J, Price DD, Mayer DJ: Thermal hyperalgesia in association with the development of morphine tolerance in rats: roles of excitatory amino acid receptors and protein kinase C. J Neurosci 1994, 14: 2301–2312.
Minville V, Fourcade O, Girolami JP, Tack I: Opioid-induced hyperalgesia in a mice model of orthopaedic pain: preventive effect of ketamine. Br J Anaesth 2010, 104: 231–238.
Vardanyan A, Wang R, Vanderah TW, Ossipov MH, Lai J, Porreca F, King T: TRPV1 receptor in expression of opioid-induced hyperalgesia. J Pain 2009, 10: 243–252.
Zollner C, Mousa SA, Fischer O, Rittner HL, Shaqura M, Brack A, Shakibaei M, Binder W, Urban F, Stein C, Schafer M: Chronic morphine use does not induce peripheral tolerance in a rat model of inflammatory pain. J Clin Investig 2008, 118: 1065–1073.
Chu LF, Angst MS, Clark D: Opioid-induced hyperalgesia in humans: molecular mechanisms and clinical considerations. Clin J Pain 2008, 24: 479–496.
DuPen A, Shen D, Ersek M: Mechanisms of opioid-induced tolerance and hyperalgesia. Pain Manag Nurs 2007, 8: 113–121.
Lee M, Silverman SM, Hansen H, Patel VB, Manchikanti L: A comprehensive review of opioid-induced hyperalgesia. Pain Physician 2011, 14: 145–161.
Low Y, Clarke CF, Huh BK: Opioid-induced hyperalgesia: a review of epidemiology, mechanisms and management. Singapore Med J 2012, 53: 357–360.
Ramasubbu C, Gupta A: Pharmacological treatment of opioid-induced hyperalgesia: a review of the evidence. J Pain Palliat Care Pharmacother 2011, 25: 219–230.
Zhao YL, Chen SR, Chen H, Pan HL: Chronic opioid potentiates presynaptic but impairs postsynaptic N-methyl-D-aspartic acid receptor activity in spinal cords: implications for opioid hyperalgesia and tolerance. J Biol Chem 2012, 287: 25073–25085.
Rowan MP, Bierbower SM, Eskander MA, Szteyn K, Por ED, Gomez R, Veldhuis N, Bunnett NW, Jeske NA: Activation of Mu opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) via beta-arrestin-2-mediated cross-talk. PLoS ONE 2014, 9: e93688.
Caterina MJ, Schumacher MA, Tominaga M, Rosen TA, Levine JD, Julius D: The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997, 389: 816–824.
Tominaga M, Caterina MJ, Malmberg AB, Rosen TA, Gilbert H, Skinner K, Raumann BE, Basbaum AI, Julius D: The cloned capsaicin receptor integrates multiple pain-producing stimuli. Neuron 1998, 21: 531–543.
Tominaga M, Tominaga T: Structure and function of TRPV1. Pflugers Arch 2005, 451: 143–150.
Wang Y: The functional regulation of TRPV1 and its role in pain sensitization. Neurochem Res 2008, 33: 2008–2012.
Lefkowitz RJ, Rajagopal K, Whalen EJ: New roles for beta-arrestins in cell signaling: not just for seven-transmembrane receptors. Mol Cell 2006, 24: 643–652.
Shukla AK, Kim J, Ahn S, Xiao K, Shenoy SK, Liedtke W, Lefkowitz RJ: Arresting a transient receptor potential (TRP) channel: beta-arrestin 1 mediates ubiquitination and functional down-regulation of TRPV4. J Biol Chem 2010, 285: 30115–30125.
Por ED, Bierbower SM, Berg KA, Gomez R, Akopian AN, Wetsel WC, Jeske NA: beta-Arrestin-2 desensitizes the transient receptor potential vanilloid 1 (TRPV1) channel. J Biol Chem 2012, 287: 37552–37563.
Gaveriaux-Ruff C, Kieffer BL: Delta opioid receptor analgesia: recent contributions from pharmacology and molecular approaches. Behav Pharmacol 2011, 22: 405–414.
Pradhan AA, Befort K, Nozaki C, Gaveriaux-Ruff C, Kieffer BL: The delta opioid receptor: an evolving target for the treatment of brain disorders. Trends Pharmacol Sci 2011, 32: 581–590.
van Rijn RM, Defriel JN, Whistler JL: Pharmacological traits of delta opioid receptors: pitfalls or opportunities? Psychopharmacology (Berl) 2013, 228: 1–18.
Vanderah TW: Delta and kappa opioid receptors as suitable drug targets for pain. Clin J Pain 2010,26(Suppl 10):S10-S15.
Bie B, Pan ZZ: Trafficking of central opioid receptors and descending pain inhibition. Mol Pain 2007, 3: 37.
Cahill CM, Holdridge SV, Morinville A: Trafficking of delta-opioid receptors and other G-protein-coupled receptors: implications for pain and analgesia. Trends Pharmacol Sci 2007, 28: 23–31.
Cowan A, Zhu XZ, Mosberg HI, Omnaas JR, Porreca F: Direct dependence studies in rats with agents selective for different types of opioid receptor. J Pharmacol Exp Ther 1988, 246: 950–955.
Zhang X, Bao L, Guan JS: Role of delivery and trafficking of delta-opioid peptide receptors in opioid analgesia and tolerance. Trends Pharmacol Sci 2006, 27: 324–329.
Jutkiewicz EM: The antidepressant -like effects of delta-opioid receptor agonists. Mol Interv 2006, 6: 162–169.
Leo RJ: Chronic pain and comorbid depression. Curr Treat Options Neurol 2005, 7: 403–412.
Scherrer G, Imamachi N, Cao YQ, Contet C, Mennicken F, O’Donnell D, Kieffer BL, Basbaum AI: Dissociation of the opioid receptor mechanisms that control mechanical and heat pain. Cell 2009, 137: 1148–1159.
Cavanaugh DJ, Lee H, Lo L, Shields SD, Zylka MJ, Basbaum AI, Anderson DJ: Distinct subsets of unmyelinated primary sensory fibers mediate behavioral responses to noxious thermal and mechanical stimuli. Proc Natl Acad Sci U S A 2009, 106: 9075–9080.
Normandin A, Luccarini P, Molat JL, Gendron L, Dallel R: Spinal mu and delta opioids inhibit both thermal and mechanical pain in rats. J Neurosci 2013, 33: 11703–11714.
Berg KA, Rowan MP, Gupta A, Sanchez TA, Silva M, Gomes I, McGuire BA, Portoghese PS, Hargreaves KM, Devi LA, Clarke WP: Allosteric interactions between delta and kappa opioid receptors in peripheral sensory neurons. Mol Pharmacol 2012, 81: 264–272.
Rowan MP, Ruparel NB, Patwardhan AM, Berg KA, Clarke WP, Hargreaves KM: Peripheral delta opioid receptors require priming for functional competence in vivo. Eur J Pharmacol 2009, 602: 283–287.
Saloman JL, Niu KY, Ro JY: Activation of peripheral delta-opioid receptors leads to anti-hyperalgesic responses in the masseter muscle of male and female rats. Neuroscience 2011, 190: 379–385.
Stein C, Millan MJ, Shippenberg TS, Peter K, Herz A: Peripheral opioid receptors mediating antinociception in inflammation. Evidence for involvement of mu, delta and kappa receptors. J Pharmacol Exp Ther 1989, 248: 1269–1275.
Fristad I, Berggreen E, Haug SR: Delta (delta) opioid receptors in small and medium-sized trigeminal neurons supporting the dental pulp of rats. Arch Oral Biol 2006, 51: 273–281.
Chen SR, Pan HL: Removing TRPV1-expressing primary afferent neurons potentiates the spinal analgesic effect of delta-opioid agonists on mechano-nociception. Neuropharmacology 2008, 55: 215–222.
Pierce KL, Lefkowitz RJ: Classical and new roles of beta-arrestins in the regulation of G-protein-coupled receptors. Nat Rev Neurosci 2001, 2: 727–733.
Qiu Y, Loh HH, Law PY: Phosphorylation of the delta-opioid receptor regulates its beta-arrestins selectivity and subsequent receptor internalization and adenylyl cyclase desensitization. J Biol Chem 2007, 282: 22315–22323.
Reiter E, Ahn S, Shukla AK, Lefkowitz RJ: Molecular mechanism of beta-arrestin-biased agonism at seven-transmembrane receptors. Annu Rev Pharmacol Toxicol 2012, 52: 179–197.
Shukla AK, Xiao K, Lefkowitz RJ: Emerging paradigms of beta-arrestin-dependent seven transmembrane receptor signaling. Trends Biochem Sci 2011, 36: 457–469.
Zuo Z: The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance. Anesth Analg 2005, 101: 728–734. table of contents
Charfi I, Nagi K, Mnie-Filali O, Thibault D, Balboni G, Schiller PW, Trudeau LE, Pineyro G: Ligand- and cell-dependent determinants of internalization and cAMP modulation by delta opioid receptor (DOR) agonists. Cell Mol Life Sci 2014, 71: 1529–1546.
Marie N, Landemore G, Debout C, Jauzac P, Allouche S: Pharmacological characterization of AR-M1000390 at human delta opioid receptors. Life Sci 2003, 73: 1691–1704.
Pradhan AA, Becker JA, Scherrer G, Tryoen-Toth P, Filliol D, Matifas A, Massotte D, Gaveriaux-Ruff C, Kieffer BL: In vivo delta opioid receptor internalization controls behavioral effects of agonists. PLoS ONE 2009, 4: e5425.
Audet N, Charfi I, Mnie-Filali O, Amraei M, Chabot-Dore AJ, Millecamps M, Stone LS, Pineyro G: Differential association of receptor-Gbetagamma complexes with beta-arrestin2 determines recycling bias and potential for tolerance of delta opioid receptor agonists. J Neurosci 2012, 32: 4827–4840.
Pradhan AA, Walwyn W, Nozaki C, Filliol D, Erbs E, Matifas A, Evans C, Kieffer BL: Ligand-directed trafficking of the delta-opioid receptor in vivo: two paths toward analgesic tolerance. J Neurosci 2010, 30: 16459–16468.
Chaudhury S, Bal M, Belugin S, Shapiro MS, Jeske NA: AKAP150-mediated TRPV1 sensitization is disrupted by calcium/calmodulin. Mol Pain 2011, 7: 34.
Diogenes A, Patwardhan AM, Jeske NA, Ruparel NB, Goffin V, Akopian AN, Hargreaves KM: Prolactin modulates TRPV1 in female rat trigeminal sensory neurons. J Neurosci 2006, 26: 8126–8136.
Por ED, Gomez R, Akopian AN, Jeske NA: Phosphorylation regulates TRPV1 association with beta-arrestin-2. Biochem J 2013, 451: 101–109.
Por ED, Samelson BK, Belugin S, Akopian AN, Scott JD, Jeske NA: PP2B/calcineurin-mediated desensitization of TRPV1 does not require AKAP150. Biochem J 2010, 432: 549–556.
Hargreaves K, Dubner R, Brown F, Flores C, Joris J: A new and sensitive method for measuring thermal nociception in cutaneous hyperalgesia. Pain 1988, 32: 77–88.
Patil MJ, Belugin S, Akopian AN: Chronic alteration in phosphatidylinositol 4,5-biphosphate levels regulates capsaicin and mustard oil responses. J Neurosci Res 2011, 89: 945–954.
Zeitelhofer M, Vessey JP, Xie Y, Tubing F, Thomas S, Kiebler M, Dahm R: High-efficiency transfection of mammalian neurons via nucleofection. Nat Protoc 2007, 2: 1692–1704.
Henry MA, Freking AR, Johnson LR, Levinson SR: Increased sodium channel immunofluorescence at myelinated and demyelinated sites following an inflammatory and partial axotomy lesion of the rat infraorbital nerve. Pain 2006, 124: 222–233.
Ruparel S, Henry MA, Akopian A, Patil M, Zeldin DC, Roman L, Hargreaves KM: Plasticity of cytochrome P450 isozyme expression in rat trigeminal ganglia neurons during inflammation. Pain 2012, 153: 2031–2039.
Wu ZZ, Chen SR, Pan HL: Differential sensitivity of N- and P/Q-type Ca2+ channel currents to a mu opioid in isolectin B4-positive and -negative dorsal root ganglion neurons. J Pharmacol Exp Ther 2004, 311: 939–947.
The authors would like to thank Elaine Por for critical discussions on the project. This work was funded by NINDS/NS082746 (NAJ) and NIDCR/DE14318 (APD) from NIH.
The authors declare that they have no competing interests.
Participated in research design: MPR, MAH, NAJ. Conducted experiments: MPR, KS, AD, RG, MAH, NAJ. Performed data analysis: MPR, KS, MAH, NAJ. Contributed to the writing of the manuscript: MPR, KS, MAH, NAJ. All authors read and approved the final manuscript.
Authors’ original submitted files for images
About this article
Cite this article
Rowan, M.P., Szteyn, K., Doyle, A.P. et al. β-arrestin-2-biased agonism of delta opioid receptors sensitizes transient receptor potential vanilloid type 1 (TRPV1) in primary sensory neurons. Mol Pain 10, 50 (2014). https://doi.org/10.1186/1744-8069-10-50
- Chronic pain